RESUMEN
BACKGROUND: Overexpression of macrophage inhibitory cytokine-1 (MIC-1) frequently occurs during the progression of prostate cancer (PC) to androgen-independent (AI) and metastatic disease states and is associated with a poor outcome of patients. METHODS: The gain- and loss-of-function analyses of MIC-1 were performed to establish its implications for aggressive and chemoresistant phenotypes of metastatic and AI PC cells and the benefit of its downregulation for reversing docetaxel resistance. RESULTS: The results have indicated that an enhanced level of secreted MIC-1 protein in PC3 cells is associated with their acquisition of epithelial-mesenchymal transition features and higher invasive capacity and docetaxel resistance. Importantly, the downregulation of MIC-1 in LNCaP-LN3 and PC3M-LN4 cells significantly decreased their invasive capacity and promoted the antiproliferative, anti-invasive and mitochrondrial- and caspase-dependent apoptotic effects induced by docetaxel. The downregulation of MIC-1 in PC3M-LN4 cells was also effective in promoting the cytotoxic effects induced by docetaxel on the side population (SP) endowed with stem cell-like properties and the non-SP cell fraction from PC3M-LN4 cells. CONCLUSION: These data suggest that the downregulation of MIC-1 may constitute a potential therapeutic strategy for improving the efficacy of current docetaxel-based chemotherapies, eradicating the total mass of PC cells and thereby preventing disease relapse and the death of PC patients.
Asunto(s)
Antagonistas de Andrógenos/uso terapéutico , Antineoplásicos/farmacología , Resistencia a Antineoplásicos , Factor 15 de Diferenciación de Crecimiento/genética , Neoplasias de la Próstata/tratamiento farmacológico , Taxoides/farmacología , Andrógenos , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Docetaxel , Regulación hacia Abajo , Transición Epitelial-Mesenquimal , Factor 15 de Diferenciación de Crecimiento/metabolismo , Humanos , Masculino , Invasividad Neoplásica , Metástasis de la Neoplasia , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patologíaRESUMEN
The fascinating discovery of tissue-resident adult stem/progenitor cells in recent years led to an explosion of interest in the development of novel stem cell-based therapies for improving the regenerative capacity of these endogenous immature cells or transplanted cells for the repair of damaged and diseased tissues. In counterbalance, a growing body of evidence has revealed that the changes in phenotypic and functional properties of human adult stem/progenitor cells may occur during chronological aging and have severe pathological consequences. Especially, intense oxidative and metabolic stress and chronic inflammation, enhanced telomere attrition and defects in DNA repair mechanisms may lead to severe DNA damages and genomic instability in adult stem/progenitor cells with advancing age that may in turn trigger their replicative senescence and/or programmed cell death. Moreover, the changes in the intrinsic and extrinsic factors involved in the stringent control of self-renewal and multilineage differentiation capacities of these regenerative cells, including deregulated signals from the aged niche, may also contribute to their dysfunctions or loss during chronological aging. This age-associated decline in the regenerative capacity and number of functional adult stem/progenitor cells may increase the risk to develop certain diseases. At opposed end, the telomerase reactivation and accumulation of genetic alterations leading to a down-regulation of numerous tumor suppressor genes concomitant with the enhanced expression of diverse oncogenic products may result in their malignant transformation into cancer-initiating cells. Therefore, the rescue or replacement of aged and dysfunctional endogenous adult stem/progenitor cells or molecular targeting of their malignant counterpart, cancer stem/progenitor cells may constitute potential anti-aging and cancer therapies. These therapeutic strategies could be used for treating diverse devastating premature aging and age-related disorders including hematopoietic and immune disorders, heart failure and cardiovascular diseases, neurodegenerative, muscular and gastrointestinal diseases, atherosclerosis and aggressive and lethal cancers.
Asunto(s)
Células Madre Adultas/patología , Envejecimiento/patología , Senescencia Celular , Trasplante de Células Madre , Células Madre Adultas/trasplante , Animales , Diferenciación Celular , Linaje de la Célula , Proliferación Celular , Transformación Celular Neoplásica/patología , Daño del ADN , Células Madre Hematopoyéticas/patología , Humanos , Células Madre Neoplásicas/patología , Estrés Oxidativo , Fenotipo , Regeneración , Trasplante de Células Madre/efectos adversosRESUMEN
Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem cell-like properties offers the possibility of stimulating their in vivo expansion and differentiation or to use their ex vivo expanded progenies for beta cell replacement-based therapies for type 1 or 2 diabetes mellitus in humans. In addition, the transplantation of either insulin-producing beta cells derived from embryonic, fetal and other tissue-resident adult stem/progenitor cells or genetically modified adult stem/progenitor cells may also constitute alternative promising therapies for treating diabetic patients. The genetic and/or epigenetic alterations in putative pancreatic adult stem/progenitor cells and/or their early progenies may, however, contribute to their acquisition of a dysfunctional behaviour as well as their malignant transformation into pancreatic cancer stem/progenitor cells. More particularly, the activation of distinct tumorigenic signalling cascades, including the hedgehog, epidermal growth factor-epidermal growth factor receptor (EGF-EGFR) system, wingless ligand (Wnt)/beta-catenin and/or stromal cell-derived factor-1 (SDF-1)-CXC chemokine receptor 4 (CXCR4) pathways may play a major role in the sustained growth, survival, metastasis and/or drug resistance of pancreatic cancer stem/progenitor cells and their further differentiated progenies. The combination of drugs that target the oncogenic elements in pancreatic cancer stem/progenitor cells and their microenvironment, with the conventional chemotherapeutic regimens, could represent promising therapeutic strategies. These novel targeted therapies should lead to the development of more effective treatments of locally advanced and metastatic pancreatic cancers, which remain incurable with current therapies.
Asunto(s)
Transformación Celular Neoplásica/patología , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Neoplasias Pancreáticas/terapia , Trasplante de Células Madre/métodos , Progresión de la Enfermedad , Resistencia a Antineoplásicos , Humanos , Trasplante de Islotes Pancreáticos/métodos , Trasplante de Páncreas/métodosRESUMEN
The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients. The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients. Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers. Recent advances have led to the identification of specific oncogenic products that are implicated in the malignant transformation of adult stem/progenitor cells into leukemic or tumorigenic and migrating cancer stem/progenitor cells during cancer progression. Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers. Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research. These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.
Asunto(s)
Recurrencia Local de Neoplasia/terapia , Neoplasias/terapia , Células Madre Neoplásicas/patología , Trasplante de Células Madre , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Progresión de la Enfermedad , Humanos , Leucemia/patología , Leucemia/terapia , Melanoma/patología , Melanoma/terapia , Recurrencia Local de Neoplasia/patología , Neoplasias/patología , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Glandulares y Epiteliales/terapia , Sarcoma/patología , Sarcoma/terapiaRESUMEN
Basic and clinical research accomplished during the last few years on embryonic, fetal, amniotic, umbilical cord blood, and adult stem cells has constituted a revolution in regenerative medicine and cancer therapies by providing the possibility of generating multiple therapeutically useful cell types. These new cells could be used for treating numerous genetic and degenerative disorders. Among them, age-related functional defects, hematopoietic and immune system disorders, heart failures, chronic liver injuries, diabetes, Parkinson's and Alzheimer's diseases, arthritis, and muscular, skin, lung, eye, and digestive disorders as well as aggressive and recurrent cancers could be successfully treated by stem cell-based therapies. This review focuses on the recent advancements in adult stem cell biology in normal and pathological conditions. We describe how these results have improved our understanding on critical and unique functions of these rare sub-populations of multipotent and undifferentiated cells with an unlimited self-renewal capacity and high plasticity. Finally, we discuss some major advances to translate the experimental models on ex vivo and in vivo expanded and/or differentiated stem cells into clinical applications for the development of novel cellular therapies aimed at repairing genetically altered or damaged tissues/organs in humans. A particular emphasis is made on the therapeutic potential of different tissue-resident adult stem cell types and their in vivo modulation for treating and curing specific pathological disorders.
Asunto(s)
Neoplasias/terapia , Medicina Regenerativa/tendencias , Trasplante de Células Madre , Células Madre/fisiología , Células Madre Adultas/fisiología , Animales , Trasplante de Médula Ósea , Células Madre Embrionarias/fisiología , Células Madre Fetales/fisiología , Trasplante de Células Madre Hematopoyéticas , Humanos , Regeneración/fisiología , Células del Estroma/trasplanteRESUMEN
In this review, we describe the critical functions assumed by the interplay of epidermal growth factor, hedgehog, Wnt/beta-catenin, tumor growth factor-beta and integrin signaling cascades in tumorigenic and migrating cancer progenitor cells and activated stromal cells during carcinogenesis. These growth factors provide an important role for the sustained growth and survival of tumorigenic cancer progenitor cells and their progeny by up-regulating numerous mitotic and antiapoptotic signaling cascades. Furthermore, these potent morphogens may cooperate for inducing the molecular events associated with the epithelial-mesenchymal program in cancer cells including the alterations in epithelial cell shape and motility through the dissociation of intercellular adherens junctions. Of therapeutic interest, new strategies for the development of more effective clinical treatments against the locally aggressive and invasive cancers based on the molecular targeting of deregulated signaling elements in tumorigenic and migrating cancer cells and their local microenvironment are also described.
Asunto(s)
Transformación Celular Neoplásica , Células Epiteliales/patología , Sustancias de Crecimiento/fisiología , Mesodermo/patología , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Células Madre Neoplásicas/fisiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Proliferación Celular , Supervivencia Celular , Citocinas/fisiología , Factor de Crecimiento Epidérmico/fisiología , Receptores ErbB/fisiología , Proteínas Hedgehog/fisiología , Humanos , Integrinas/fisiología , Metástasis de la Neoplasia , Células Madre Neoplásicas/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , beta Catenina/fisiologíaRESUMEN
A structure-activity study was carried out to determine the importance of the N-terminal amino acids of hCGRP8-37 in binding and antagonistic activity to CGRP receptors. Therefore, fragments of hCGRP8-37 as well as analogs obtained by the replacement of residues 9-12 by L-alanine were synthesized by solid-phase peptide synthesis, using BOP as a coupling reagent. The affinities of the peptides to CGRP receptors were evaluated in the rat brain, guinea pig atrium, and guinea pig vas deferens membrane preparations. Their antagonistic activities were measured in the guinea pig atria and rat vas deferens bioassays. The pharmacological characterization showed that arginine-11 and leucine-12 play a crucial role for the affinity of hCGRP8-37. Interestingly, it was observed that [Ala11]hCGRP8-37 was able to potentiate the twitch response of the electrically stimulated rat vas deferens. On the other hand, the substantial antagonistic potencies of analogs [Ala9]-, [Ala10]-, and [Ala12]hCGRP8-37, as compared to those of the fragments hCGRP10-37, hCGRP11-37, and hCGRP12-37, suggest that the side chains of Thr-9, His-10, and Leu-12 assume mainly a structural role. Accordingly, the conformational characterization of these peptides by circular dichroism spectroscopy revealed that the residues 9-12 are important for the integrity of the amphiphilic alpha-helix of hCGRP8-37.
Asunto(s)
Péptido Relacionado con Gen de Calcitonina/química , Péptido Relacionado con Gen de Calcitonina/farmacología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/farmacología , Receptores de Superficie Celular/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Encéfalo/metabolismo , Péptido Relacionado con Gen de Calcitonina/metabolismo , Membrana Celular/metabolismo , Cromatografía Líquida de Alta Presión , Estimulación Eléctrica , Cobayas , Atrios Cardíacos/metabolismo , Masculino , Datos de Secuencia Molecular , Fragmentos de Péptidos/metabolismo , Conformación Proteica , Ratas , Ratas Endogámicas , Receptores de Calcitonina , Relación Estructura-Actividad , Conducto DeferenteRESUMEN
Accumulating lines of experimental evidence have revealed that the malignant transformation of multipotent tissue-resident adult stem/progenitor cells into cancer stem/progenitor cells endowed with a high self-renewal capacity and aberrant multilineage differentiation potential may be at origin of the most types of human aggressive and recurrent cancers. Based on new cancer stem/progenitor cell concepts of carcinogenesis, it is suggested that a small subpopulation of highly tumorigenic and migrating cancer stem/progenitor cells, also designated as cancer- and metastasis-initiating cells, can provide critical roles for primary tumor growth, metastases at distant tissues and organs, treatment resistance and disease relapse. Particularly, cancer initiation and progression to locally invasive and metastatic stages is often associated with a persistent activation of distinct developmental signaling pathways in these immature cells during epithelial-mesenchymal transition program. The signaling cascades that are often deregulated in cancer stem/progenitor cells include hedgehog, epidermal growth factor receptor (EGFR), Wnt/beta-catenin, NOTCH, polycomb gene product BMI-1 and/or stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4). Importantly, the results from recent investigations have also indicated that different cancer subtypes may harbor distinct subsets and/or number of cancer-initiating cells during cancer progression as well as before or after therapy initiation and disease recurrence. Therefore, the identification of the molecular transforming events that frequently occur in cancer- and metastasis-initiating cells versus their differentiated progenies is of immense interest to develop new targeting approach for improving current therapies against aggressive, metastatic, recurrent and lethal cancers.
Asunto(s)
Neoplasias/patología , Neoplasias/terapia , Adulto , Diferenciación Celular , Transformación Celular Neoplásica/patología , Células/patología , Progresión de la Enfermedad , Receptores ErbB , Humanos , Procesos Neoplásicos , Recurrencia , Transducción de Señal , Células Madre/patología , beta CateninaAsunto(s)
Encéfalo/metabolismo , Péptido Relacionado con Gen de Calcitonina/síntesis química , Péptido Relacionado con Gen de Calcitonina/farmacología , Corazón/fisiología , Músculo Liso/fisiología , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/farmacología , Receptores de Superficie Celular/metabolismo , Animales , Péptido Relacionado con Gen de Calcitonina/metabolismo , Membrana Celular/metabolismo , Cobayas , Corazón/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , Miocardio/metabolismo , Fragmentos de Péptidos/metabolismo , Ratas , Receptores de Calcitonina , Relación Estructura-Actividad , Conducto Deferente/efectos de los fármacos , Conducto Deferente/fisiologíaRESUMEN
This review summarizes the recent knowledge obtained on the molecular mechanisms involved in the intrinsic and acquired resistance of cancer cells to current cancer therapies. We describe the cascades that are often altered in cancer cells during cancer progression that may contribute in a crucial manner to drug resistance and disease relapse. The emphasis is on the implication of ATP-binding cassette (ABC) multidrug efflux transporters in drug disposition and antiapoptotic factors, including epidermal growth factor receptor cascades and deregulated enzymes in ceramide metabolic pathways. The altered expression and activity of these signaling elements may have a critical role in the resistance of cancer cells to cytotoxic effects induced by diverse chemotherapeutic drugs and cancer recurrence. Of therapeutic interest, new strategies for reversing the multidrug resistance and developing more effective clinical treatments against the highly aggressive, metastatic, and recurrent cancers, based on the molecular targeting of the cancer progenitor cells and their further differentiated progeny, are also described.
Asunto(s)
Resistencia a Antineoplásicos , Neoplasias/tratamiento farmacológico , Neoplasias/genética , Transportadoras de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/metabolismo , Humanos , Neoplasias/metabolismo , FarmacogenéticaRESUMEN
Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers. This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant transformation of adult stem/progenitor cells. We describe the critical functions provided by several growth factor cascades, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/beta-catenin signalling pathways that are frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and drug resistance. Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which remain incurable in the clinics. The emphasis is on new therapeutic strategies consisting of molecular targeting of distinct oncogenic signalling elements activated in the cancer progenitor cells and their local microenvironment during cancer progression. These new targeted therapies should improve the efficacy of current therapeutic treatments against aggressive cancers, and thereby preventing disease relapse and enhancing patient survival.
Asunto(s)
Resistencia a Antineoplásicos , Neoplasias/terapia , Células Madre Neoplásicas/patología , Animales , Progresión de la Enfermedad , Humanos , Neoplasias/clasificación , Neoplasias/patologíaAsunto(s)
Oncología Médica/tendencias , Neoplasias/patología , Neoplasias/terapia , Células Madre Neoplásicas/patología , Animales , Separación Celular/métodos , Separación Celular/tendencias , Humanos , Invasividad Neoplásica , Metástasis de la Neoplasia , Células Madre Neoplásicas/fisiología , RecurrenciaRESUMEN
The functional characterization of ETS transcription factors have allowed the association of numerous physiological and pathological roles to these proteins in the regulation of gene expression during the maturation of hematopoietic cell lineages and in tumor cell growth, invasion, and metastasis. Moreover, structural investigations have allowed the determination of certain amino acid domains of ETS proteins that are essential for the recognition and transcriptional activation or repression of gene promoters or enhancers. It has been observed that the mechanisms of action of ETS proteins can be ruled in part by their intermolecular interactions with other transcription factors and by their phosphorylation status. This review describes information about structure-function relationships of different ETS family members in order to establish the structural differences that are important for their affinities and intrinsic activities to DNA binding sites.
Asunto(s)
Proteínas Proto-Oncogénicas/química , Proteínas Proto-Oncogénicas/fisiología , Factores de Transcripción/química , Factores de Transcripción/fisiología , Secuencia de Aminoácidos , Secuencia de Bases , Predicción , Humanos , Datos de Secuencia Molecular , Conformación Proteica , Proteínas Proto-Oncogénicas c-ets , Proteínas Oncogénicas de Retroviridae/fisiología , Homología de Secuencia de Aminoácido , Homología de Secuencia de Ácido Nucleico , Relación Estructura-ActividadRESUMEN
A conformational study by circular-dichroism spectroscopy of calcitonin-gene-related peptide (CGRP) and related fragments and analogs was carried out in structure-promoting solvent mixtures. The structural characterization of rat CGRP alpha and the two isoforms of human CGRP, alpha and beta, revealed that these peptides possess very similar conformational features. The far-ultraviolet circular-dichroism spectra, in pure water, of human CGRP alpha, (hCGRP alpha), [Acm-Cys2,7]hCGRP alpha, various fragments and analogs indicated that these peptides exhibited predominantly a random-coil conformation. The addition of increasing concentrations of 1,1,1,3,3,3-hexafluoro-2-propanol to the peptide solutions resulted in a transition from a random-coil conformation to a stabilized alpha-helical structure. The substantial loss of helical content measured with [Acm-Cys2,7]hCGRP alpha, [Acm-Cys2,7]hCGRP-(1-24)-CONH2 and hCGRP-(8-37), compared to hCGRP alpha, suggested that the N-terminal disulfide bridge of hCGRP alpha is essential for adopting a highly stabilized alpha-helical conformation. Moreover, the lower helical content of hCGRP-(8-37), as compared to [Acm-Cys2,7]hCGRP alpha, as well as spectroscopic results measured with various fragments and analogs of hCGRP-(8-37) revealed that N-terminal residues found in the peptide segment 1-12 are important for the full conservation of the amphiphilic alpha-helix. In addition, the similar alpha-helical content of hCGRP-(8-37) and hCGRP-(8-18) indicated that the C-terminal segment 19-37 is not essential for the stabilization of the alpha-helix structure.
Asunto(s)
Péptido Relacionado con Gen de Calcitonina/química , Fragmentos de Péptidos/química , Secuencia de Aminoácidos , Péptido Relacionado con Gen de Calcitonina/análogos & derivados , Dicroismo Circular , Datos de Secuencia Molecular , Conformación Proteica , Estructura Secundaria de ProteínaRESUMEN
A pharmacological characterization of subtypes of the atrial natriuretic factor (ANF) receptor ANF-R1, found in bovine adrenal cortex and rat papillary membrane preparations, has been carried out using various chimeric analogs based on rat ANF(99-126) [rANF(99-126)] and porcine brain natriuretic peptide 32 (pBNP32). Receptor binding and cGMP production assays in bovine adrenal cortex indicate that replacement of the amino-terminal segment of pBNP32 with that of rANF(99-126) enhances the affinity of the peptide for the ANF-R1A receptor subtype and its stimulation of associated guanylate cyclase activity. In rat kidney papillae, the substitution of amino- and/or carboxyl-terminal portions of pBNP32 with those of rANF(99-126) also results in a large increase in the affinity and agonistic potency for the ANF-R1A subtype but in only modest changes in those for the ANF-R1B receptor subtype. Interestingly, in this preparation the chimeric analogs could discriminate by their differential affinities and cGMP production potencies between the two receptor subtypes. In particular, pBNP1, obtained by combining the ring structure of pBNP32 with the amino- and carboxyl-terminal portions of rANF(99-126), is the most selective analog. pBNP1 displays higher affinity and agonistic potency for ANF-R1A receptor than for ANF-R1B receptor, with selectivity ratios between these two subtypes of 632- and 504-fold, respectively. Moreover, an excellent correlation is observed between the affinity of the peptides for the ANF-R1A receptor and their stimulation of particulate guanylate cyclase activity in bovine adrenal cortex (r = 0.99, p < 0.01) and rat papillary (r = 0.97, p < 0.01) membrane preparations. In addition, all the chimeric analogs in this study show affinities similar to those of rANF(99-126) and pBNP32 for the ANF-R2 receptor in NIH-3T3 membrane preparations. Importantly, the chimeric analogs pBNP1 and pBNP3, which contain the core of pBNP32 and the amino-terminal segment of rANF(99-126), display higher affinities for the ANF-R1A receptor type than for the ANF-R2 receptor type. These results indicate that the analogs combining the ring structure of pBNP32 with the amino- and/or carboxyl-terminal segments of rANF(99-126) are more selective for the ANF-R1A receptor subtype than are the natural peptides rANF(99-126) and pBNP32.
Asunto(s)
Factor Natriurético Atrial/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Fragmentos de Péptidos/metabolismo , Receptores del Factor Natriurético Atrial/metabolismo , Células 3T3 , Secuencia de Aminoácidos , Animales , Factor Natriurético Atrial/síntesis química , Unión Competitiva , Bovinos , Técnicas In Vitro , Masculino , Ratones , Datos de Secuencia Molecular , Péptido Natriurético Encefálico , Proteínas del Tejido Nervioso/síntesis química , Fragmentos de Péptidos/síntesis química , Ensayo de Unión Radioligante , Ratas , Relación Estructura-ActividadRESUMEN
Photoacoustic spectroscopy was used to monitor photo synthetic electron transfer in native and immobilized thylakoid membranes. The photoacoustic parameter phi(r)' (the percentage of absorbed energy that is stored in photo chemical intermediates) and i(50) (the half-saturation modulated light intensity) were directly correlated to electron transfer rates. As previously shown, thylakoids immobilized in an albumin-glutaraldehyde matrix were more resistant to aging. The inhibitory effects of the immobilization procedure and of aging at 4 degrees C were detected as a decrease in i(50) values. In analogy with enzyme kinetic analysis, the effect could be characterized as a competitive type of inhibition. Photoacoustic measurements are performed in conditions similar to a working bioreactor cell with regards to the sample preparation.
RESUMEN
The photosynthetic energy storage yield of uncoupled thylakoid membranes was monitored by photoacoustic spectroscopy at various measuring beam intensities. The energy storage rate as evaluated by the half-saturation measuring beam intensity (i50) was inhibited by 3-(3,4-dichlorophenyl)-1,1 dimethylurea, by heat inactivation or by artificial electron acceptors specific for photosystem I or photosystem II; and was activated by electron donors to photosystem I. The reactions involving both photosystems were all characterized by a similar maximal energy storage yield of 16±2 percent. The data could be interpreted if we assumed that the energy storage elicited by the photosystems at 35 Hz is detected at the level of the plastoquinone pool.
RESUMEN
Recent advances in understanding of the biological functions of the epidermal growth factor and epidermal growth factor receptor (EGF-EGFR) system and ceramide production for the maintenance of skin integrity and barrier function are reported. In particular, the opposite roles of EGFR and ceramide cascades in epithelial keratinocyte proliferation, migration and terminal differentiation are described. Moreover, the functions of ceramides in the epidermal permeability barrier are reviewed. The alterations in EGFR signaling and ceramide metabolism, which might be involved in the etiopathogenesis of diverse skin disorders and cancers, are described. New progress in understanding of skin organization, which might provide the basis for the design of new transcutaneous drug delivery techniques as well as for the development of new therapies of skin disorders and cancers, are reported.
Asunto(s)
Ceramidas/metabolismo , Receptores ErbB/metabolismo , Enfermedades de la Piel/metabolismo , Neoplasias Cutáneas/metabolismo , Piel/metabolismo , Administración Cutánea , Diferenciación Celular/fisiología , Ceramidas/biosíntesis , Ceramidas/uso terapéutico , Quimioterapia Combinada , Células Epidérmicas , Epidermis/metabolismo , Receptores ErbB/antagonistas & inhibidores , Permeabilidad , Piel/citología , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/etiología , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/etiología , Regulación hacia ArribaRESUMEN
Recent data have suggested that N-truncated human calcitonin gene-related peptide (hCGRP) fragments such as hCGRP8-37 and hCGRP12-37 behave as competitive antagonists in certain bioassays. The present study was undertaken to determine which amino acid residues between positions 8 to 12 are directly involved in ensuring high affinity and antagonist properties at CGRP receptors. In brain, atrium and vas deferens membrane preparations, hCGRP8-37 and hCGRP9-37 demonstrated affinities similar to or much higher than that of the native peptide hCGRP alpha. Shorter fragments such as hCGRP 10-37 and hCGRP 11-37 possessed less than 20% of the affinity of hCGRP alpha in these various assays demonstrating the critical importance of the Thr residue in position 9 for maintenance of adequate receptor affinity. In the in vitro guinea pig left and right atria bioassays, both hCGRP8-37 and hCGRP9-37 behaved as potent and competitive antagonists (pA2:7.0-7.7) of positive chronotropic and inotropic effects induced by hCGRP alpha. hCGRP 10-37 and hCGRP 11-37 were at least 10 times less potent (pA2: 6.1-6.6). Interestingly, both hCGRP 8-37 and hCGRP9-37 were much less potent (pA2: 6.2-6.3) in blocking the effects of hCGRP alpha in the rat vas deferens whereas only slight inhibition was observed at 1.0 microM with hCGRP10-37 and no blocking activity was detected with hCGRP11-37 at a low micromolar concentration. These results are in accordance with binding data and demonstrate further the importance of residues in positions 9 (Thr) and 10 (His) to ensure potent antagonistic properties of N-truncated hCGRP fragments.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Encéfalo/metabolismo , Péptido Relacionado con Gen de Calcitonina/metabolismo , Fragmentos de Péptidos/metabolismo , Receptores de Superficie Celular/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Encéfalo/ultraestructura , Cobayas , Atrios Cardíacos/ultraestructura , Radioisótopos de Yodo , Cinética , Masculino , Datos de Secuencia Molecular , Miocardio/metabolismo , Ratas , Ratas Endogámicas , Receptores de Calcitonina , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Superficie Celular/metabolismo , Conducto Deferente/metabolismo , Conducto Deferente/ultraestructuraRESUMEN
The conformational properties of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), and various analogs and homologs were studied by circular dichroism (CD) spectroscopy in solvent mixtures inducing secondary structures. The CD spectra obtained for rat ANF(99-126), porcine BNP32, and their related analogs indicated that these peptides exhibited mainly a random-coil conformation in pure water. However, the addition of increasing concentrations of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) gave rise for all peptides to a more ordered secondary structure. The analysis of the far-ultraviolet CD spectra suggested that the peptides exist under two conformational states, beta-turn and beta-sheet, in the presence of 20-60% HFIP/water solutions. Moreover, the characterizations of rANF(99-126) and the analog pBNP1, which combines the cyclic core of bBNP32 with the carboxy- and amino-terminal segments of rANF-(99-126), have been carried out by Fourier transform infrared spectroscopy (FTIR) in 40% HFIP/D2O. The FTIR results indicated that these peptides exist predominantly under a beta-turn and beta-sheet mixed conformation. In addition, the amount of organized secondary structure obtained for human BNP32, bovine aldosterone secretion inhibitory factor, also known as ASIF(69-103) and beta-rANF(92-126), in the presence of a 40% HFIP/phosphate buffer mixture, was similar to that of porcine BNP32, whereas rat BNP32 was found to be more structured. In the same solvent mixture, the CD spectra of Met(O)110-human ANF(99-126) and chicken ANF(99-126) indicated that these peptides possess conformational features different to those of rANF(99-126) and hANF(99-126). Porcine CNP22, C-type natriuretic peptide, and the fragment C-ANF exhibited undefined secondary structure in the presence of 40% HFIP/phosphate buffer. These results suggest that the amino acid residues, not common to the various natriuretic peptides, would be involved in the stabilization of either beta-turn and/or beta-sheet conformations. Moreover, these secondary structures appear as particularly important for the recognition of the ANF-R1A receptor subtype found in bovine adrenal cortex.